Biogen Idec, Inc. (Massachusetts) (BIIB) Showcases Commitment to Advancing Hemophilia Treatment and Care at ISTH Congress
6/24/2013 7:48:12 AM
Sign up for the free GenePool newsletter today!
Biogen Idec (NASDAQ: BIIB) will showcase new data from a number of development and early-stage research programs at the XXIV International Society on Thrombosis and Haemostasis (ISTH) Congress. Researchers will present 33 abstracts on clinical and pre-clinical research in hemophilia, the breadth of which reflects the company’s commitment to innovation and the scientific advancement of hemophilia treatment and care. The ISTH Congress will be held June 29 through July 4 in Amsterdam, The Netherlands.
Help employers find you! Check out all the jobs and post your resume.
comments powered by